

Supplementary Table 2. Summary of Sensitivity Analysis Regarding Types of ICI

Outcome	Total		Anti-CTLA-4		Anti-PD-1		<i>P</i>
	Proportion	<i>I</i> ²	Proportion	<i>I</i> ²	Proportion	<i>I</i> ²	
Intracranial ORR	15 (11–20)	0	13 (9–18)	0	19 (11–33)	19	0.28
Intracranial DCR	26 (21–32)	0	27 (21–34)	0	24 (15–36)	0	0.62
Intracranial CR	6 (2–15)	57	3 (1–6)	0	12 (5–26)	31	< 0.01
Grade 3/4 AE*	11 (8–17)	0	10 (6–17)	-	15 (7–29)	-	-
CNS-related grade 3/4 AE	5 (3–8)	8	5 (2–13)	54	5 (2–14)	0	0.95

Anti-CTLA-4 includes ipilimumab, Anti-PD-1 includes nivolumab and pembrolizumab. *Sensitivity analysis was not available because only one study reported data regarding grade 3/4 AE when using ipilimumab and nivolumab each. Anti-CTLA-4 = cytotoxic T-lymphocyte-associated protein 4, Anti-PD-1 = programmed cell death protein 1, CR = achieving complete, DCR = disease control rate (proportion of the patients who were confirmed as CR, PR, or SD, ORR = objective response rate (proportion of the patients who were confirmed as CR or PR), PR = partial response, SD = stable disease